Charles Schwab Investment Management Inc. Has $6.63 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• Charles Schwab Investment Management Inc. increased its stake in GSK PLC by 35.1%, acquiring an additional 44,498 shares to a total of 171,145 shares worth approximately $6.63 million.
• GSK recently reported quarterly earnings of $1.23 per share, surpassing expectations, with revenue of $10.64 billion compared to estimates of $7.92 billion.
• The company announced a quarterly dividend of $0.4206 per share, representing an annual yield of 4.2%, despite a payout ratio of 77.78%.

Charles Schwab Investment Management Inc. grew its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 35.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 171,145 shares of the pharmaceutical company's stock after buying an additional 44,498 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in GSK were worth $6,630,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Primecap Management Co. CA boosted its holdings in GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock worth $995,929,000 after purchasing an additional 446,360 shares during the last quarter. Equity Investment Corp increased its holdings in shares of GSK by 5.3% during the 1st quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after acquiring an additional 211,608 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of GSK by 0.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock worth $87,884,000 after acquiring an additional 18,492 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of GSK by 68.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock worth $75,656,000 after acquiring an additional 907,068 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its holdings in shares of GSK by 1,360.4% during the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after acquiring an additional 2,016,795 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

GSK has been the topic of several research analyst reports. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Stock Performance

NYSE:GSK traded up $0.24 during mid-day trading on Friday, reaching $39.68. 3,590,956 shares of the company's stock were exchanged, compared to its average volume of 3,181,567. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.26. The firm has a market capitalization of $80.82 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 1.72 and a beta of 0.51. The business's fifty day simple moving average is $38.40 and its two-hundred day simple moving average is $38.24. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK's payout ratio is presently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.